AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer

A Aytatli, N Barlak, F Sanli, HO Caglar, B Gundogdu… - Cellular Oncology - Springer
Purpose Development of chemoresistance is one of the major obstacles to the treatment of
head and neck squamous cell carcinoma (HNSCC). The PI3K/Akt pathway, involved in drug …
被引用次数：19 相关文章

AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.

A Aytatli, N Barlak, F Sanli, HO Caglar… - Cellular Oncology …, 2022 - search.ebscohost.com
Purpose: Development of chemoresistance is one of the major obstacles to the treatment of
head and neck squamous cell carcinoma (HNSCC). The PI3K/Akt pathway, involved in drug …

AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer

A Aytatli, N Barlak, F Sanli… - Cellular oncology …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Development of chemoresistance is one of the major obstacles to the treatment of
head and neck squamous cell carcinoma (HNSCC). The PI3K/Akt pathway, involved in drug …

AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer

A Aytatli, N Barlak, F Sanli, H Caglar… - CELLULAR …, 2022 - avesis.atauni.edu.tr
Purpose Development of chemoresistance is one of the major obstacles to the treatment of
head and neck squamous cell carcinoma (HNSCC). The PI3K/Akt pathway, involved in drug …

AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.

A Aytatli, N Barlak, F Sanli, HO Caglar… - Cellular Oncology …, 2021 - europepmc.org
Purpose Development of chemoresistance is one of the major obstacles to the treatment of
head and neck squamous cell carcinoma (HNSCC). The PI3K/Akt pathway, involved in drug …